# VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

> **NCT00440765** · — · COMPLETED · sponsor: **Janssen-Cilag B.V.** · enrollment: 331 (actual)

## Conditions studied

- Multiple Myeloma
- Hematological Neoplasms

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00440765
- **Lead sponsor:** Janssen-Cilag B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440765, "VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00440765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*